Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
The Infectious Diseases Society of America has released its 2026 update to guidance on treating antimicrobial-resistant (AMR) gram-negative infections — and this one's a big refresh. Every single question from the 2024 version was revised based on new clinical or preclinical data. The update covers preferred vs. alternative treatment strategies, oral therapy transitions, and how to incorporate newly FDA-approved antibiotics into practice.
The Infectious Diseases Society of America (IDSA) has released its 2026 update to guidance on treating antimicrobial-resistant (AMR) gram-negative infections in the U.S. — and it's the most comprehensive revision yet. Every question from the 2024 guidance was revised in some way, driven by a wave of new preclinical and clinical data, including findings from randomized clinical trials like the Game Changer trial, which clarified the role of cefiderocol in AMR treatment.
The update also reflects a rapidly changing antibiotic landscape. Several new agents recently received FDA approval for UTIs caused by AMR pathogens — including oral sulopenem, gepotidacin, pivmecillinam, and IV fosfomycin — and the guidance helps clinicians understand how to incorporate them. Notably, cefepime-zidebactam and oral tebipenem were approved between submission and publication, and will be addressed in the next update.
Key Takeaways:
Why it matters: With AMR infections growing more complex and the antibiotic pipeline evolving fast, clinicians need up-to-date, practical guidance. IDSA plans to keep refreshing this resource every 1–2 years to help providers navigate an increasingly difficult treatment landscape.
